← SGLT2 inhibitors × adverse events & safety

ArticleDiabetes, obesity & metabolism2017

Urinary tract and genital infections in patients with type 2 diabetes treated with sodium-glucose co-transporter 2 inhibitors: A meta-analysis of randomized controlled trials.

Dandan Li et al.PubMed ↗Publisher ↗

  • Dapagliflozin 2.5 mglooks bad hereMore genital infections.Randomised, small.
  • Canagliflozin 300 mglooks bad hereMore genital infections.Randomised, small.

What the trial testedrandomised · 689 people · 2017

Randomised vs placebo

Probably increased genital infections

3.2×2.1× to 4.9×

dapagliflozin 2.5 mg vs placebo

Bigger than 9 in 10 for adverse events & safety

As reported

OR 3.21, 95% CI 2.08–4.93

Randomised vs placebo

Probably increased genital infections

5.2×3.9× to 7.1×

canagliflozin 300 mg vs placebo

Bigger than almost all for adverse events & safety

As reported

OR 5.23, 95% CI 3.86–7.09

Who was studied, and how

689people with type 2 diabetes, in this paper

The trial randomly assignedassigned by chance

dapagliflozin 2.5 mg
placebo

Probably increased genital infections3.2×

randomised

The trial randomly assignedassigned by chance

canagliflozin 300 mg
placebo

Probably increased genital infections5.2×

randomised

the abstract, start to end

… than placebo, with ORs ranging from 3.21 (95% CI 2.08-4.93) for dapagliflozin 2.5 mg to 5.23 (95% CI 3.86-7.09) for …

← favours treatmentfavours comparator →
could be chance
Genital infectionsdapagliflozin 2.5 mg vs placebo
OR 3.212.08–4.93
Genital infectionscanagliflozin 300 mg vs placebo
OR 5.233.86–7.09
SGLT2 inhibitorsAdverse events & safety

SGLT2 inhibitors × adverse events & safetyharms?mixed

unlikelylikely
0.00not counted
← favours treatmentfavours comparator →
more certainless certain
1 / 6

134 papers cite itlatest 60 shown

2017
…
2018
2019
2020
2021
2022
2023
2024
2025
2026
this paperpooled itcites it

The trial

NCT0473504260 enrolled2020
Full record →Abstract, authors, funding and every citing paper · PMID 27862830